227 related articles for article (PubMed ID: 18759762)
1. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.
Rezvani AR; Norasetthada L; Gooley T; Sorror M; Bouvier ME; Sahebi F; Agura E; Chauncey T; Maziarz RT; Maris M; Shizuru J; Bruno B; Bredeson C; Lange T; Yeager A; Sandmaier BM; Storb RF; Maloney DG
Br J Haematol; 2008 Nov; 143(3):395-403. PubMed ID: 18759762
[TBL] [Abstract][Full Text] [Related]
2. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
[TBL] [Abstract][Full Text] [Related]
4. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
Hamadani M; Hari PN; Zhang Y; Carreras J; Akpek G; Aljurf MD; Ayala E; Bachanova V; Chen AI; Chen YB; Costa LJ; Fenske TS; Freytes CO; Ganguly S; Hertzberg MS; Holmberg LA; Inwards DJ; Kamble RT; Kanfer EJ; Lazarus HM; Marks DI; Nishihori T; Olsson R; Reddy NM; Rizzieri DA; Savani BN; Solh M; Vose JM; Wirk B; Maloney DG; Smith SM; Montoto S; Saber W; Alpdogan O; Cashen A; Dandoy C; Finke R; Gale R; Gibson J; Hsu JW; Janakiraman N; Laughlin MJ; Lill M; Cairo MS; Munker R; Rowlings PA; Schouten HC; Shea TC; Stiff PJ; Waller EK
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1729-36. PubMed ID: 25008330
[TBL] [Abstract][Full Text] [Related]
5. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.
Hamadani M; Saber W; Ahn KW; Carreras J; Cairo MS; Fenske TS; Gale RP; Gibson J; Hale GA; Hari PN; Hsu JW; Inwards DJ; Kamble RT; Klein A; Maharaj D; Marks DI; Rizzieri DA; Savani BN; Schouten HC; Waller EK; Wirk B; Laport GG; Montoto S; Maloney DG; Lazarus HM
Biol Blood Marrow Transplant; 2013 May; 19(5):746-53. PubMed ID: 23380340
[TBL] [Abstract][Full Text] [Related]
6. Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.
Avivi I; Canals C; Vernant JP; Wulf G; Nagler A; Hermine O; Petersen E; Yakoub-Agha I; Craddock C; Schattenberg A; Niederwieser D; Thomson K; Blaise D; Attal M; Pfreundschuh M; Passweg J; Russell N; Dreger P; Sureda A;
Bone Marrow Transplant; 2014 May; 49(5):671-8. PubMed ID: 24510071
[TBL] [Abstract][Full Text] [Related]
7. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
[TBL] [Abstract][Full Text] [Related]
8. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.
Shustov AR; Gooley TA; Sandmaier BM; Shizuru J; Sorror ML; Sahebi F; McSweeney P; Niederwieser D; Bruno B; Storb R; Maloney DG
Br J Haematol; 2010 Jul; 150(2):170-8. PubMed ID: 20507311
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation.
Fenske TS; Ahn KW; Graff TM; DiGilio A; Bashir Q; Kamble RT; Ayala E; Bacher U; Brammer JE; Cairo M; Chen A; Chen YB; Chhabra S; D'Souza A; Farooq U; Freytes C; Ganguly S; Hertzberg M; Inwards D; Jaglowski S; Kharfan-Dabaja MA; Lazarus HM; Nathan S; Pawarode A; Perales MA; Reddy N; Seo S; Sureda A; Smith SM; Hamadani M
Br J Haematol; 2016 Jul; 174(2):235-48. PubMed ID: 26989808
[TBL] [Abstract][Full Text] [Related]
11. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.
Rezvani AR; Storer B; Maris M; Sorror ML; Agura E; Maziarz RT; Wade JC; Chauncey T; Forman SJ; Lange T; Shizuru J; Langston A; Pulsipher MA; Sandmaier BM; Storb R; Maloney DG
J Clin Oncol; 2008 Jan; 26(2):211-7. PubMed ID: 18056679
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
13. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N
Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569
[TBL] [Abstract][Full Text] [Related]
14. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.
Dreger P; Sureda A; Ahn KW; Eapen M; Litovich C; Finel H; Boumendil A; Gopal A; Herrera AF; Schmid C; Diez-Martin JL; Fuchs E; Bolaños-Meade J; Gooptu M; Al Malki MM; Castagna L; Ciurea SO; Dominietto A; Blaise D; Ciceri F; Tischer J; Corradini P; Montoto S; Robinson S; Gülbas Z; Hamadani M
Blood Adv; 2019 Feb; 3(3):360-369. PubMed ID: 30723110
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
17. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
Baron F; Zachée P; Maertens J; Kerre T; Ory A; Seidel L; Graux C; Lewalle P; Van Gelder M; Theunissen K; Willems E; Emonds MP; De Becker A; Beguin Y
J Hematol Oncol; 2015 Feb; 8():4. PubMed ID: 25652604
[TBL] [Abstract][Full Text] [Related]
18. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
19. R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.
Modi D; Kim S; Surapaneni M; Ayash L; Alavi A; Ratanatharathorn V; Deol A; Uberti JP
Biol Blood Marrow Transplant; 2020 Apr; 26(4):683-690. PubMed ID: 31682979
[TBL] [Abstract][Full Text] [Related]
20. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]